Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

(2012) S. Pianko et al.   JOURNAL OF VIRAL HEPATITIS

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

(2011) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

(2011) Paul W Noble et al.   LANCET

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3

(2010) David R. Nelson et al.   GASTROENTEROLOGY

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1

(2010) Stefan Zeuzem et al.   GASTROENTEROLOGY

Chronic cough associated with interferon/ribavirin therapy for hepatitis C

(2010) P. V. Dicpinigaitis et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

The complex interrelationships between chronic lung and liver disease: a review

(2010) P. Spagnolo et al.   JOURNAL OF VIRAL HEPATITIS

Pneumonitis as A Consequence of (Peg)Interferon-Ribavirin Combination Therapy for Hepatitis C: a Review of the Literature

(2009) Serena Slavenburg et al.   DIGESTIVE DISEASES AND SCIENCES

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis

(2008) Yasuji Arase et al.   WORLD JOURNAL OF GASTROENTEROLOGY